What is THERIVA BIOLOGICS INC's earnings per share (EPS)?

THERIVA BIOLOGICS INC (TOVX) reported diluted earnings per share of $-2.08 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

THERIVA BIOLOGICS INC Financials

TOVX

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows THERIVA BIOLOGICS INC (TOVX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 16 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

2/9

THERIVA BIOLOGICS INC passes 2 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality Low Quality

0.70x

For every $1 of reported earnings, THERIVA BIOLOGICS INC generates $0.70 in operating cash flow (-$16.7M OCF vs -$23.7M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-394.3x

THERIVA BIOLOGICS INC earns $-394.3 in operating income for every $1 of interest expense (-$24.1M vs $61K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$23.9M

YoY+8.6%

THERIVA BIOLOGICS INC's EBITDA was -$23.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 8.6% from the prior year.

Net Income

-$23.7M

YoY+7.5%

THERIVA BIOLOGICS INC reported -$23.7M in net income in fiscal year 2025. This represents an increase of 7.5% from the prior year.

EPS (Diluted)

$-2.08

THERIVA BIOLOGICS INC earned $-2.08 per diluted share (EPS) in fiscal year 2025. This represents an increase of 89.1% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$16.7M

YoY+1.4%

THERIVA BIOLOGICS INC generated -$16.7M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 1.4% from the prior year.

Cash & Debt

$13.1M

YoY+12.5%

5Y CAGR+16.0%

10Y CAGR-4.6%

THERIVA BIOLOGICS INC held $13.1M in cash against $1.7M in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

36M

THERIVA BIOLOGICS INC had 36M shares outstanding in fiscal year 2025. This represents an increase of 1182.6% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-154.3%

YoY-19.8pp

10Y CAGR+118.2pp

THERIVA BIOLOGICS INC's ROE was -154.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 19.8 percentage points from the prior year.

Capital Allocation

R&D Spending

$8.6M

YoY-28.5%

5Y CAGR+10.9%

10Y CAGR-12.6%

THERIVA BIOLOGICS INC invested $8.6M in research and development in fiscal year 2025. This represents a decrease of 28.5% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$35K

YoY+3400.0%

5Y CAGR+31.2%

10Y CAGR-23.4%

THERIVA BIOLOGICS INC invested $35K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 3400.0% from the prior year.

TOVX Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$8.6M-28.5%	$12.0M-15.9%	$14.3M+22.1%	$11.7M+50.3%	$7.8M+52.0%	$5.1M
SG&A Expenses	$15.4M+108.9%	$7.4M+3.9%	$7.1M-27.8%	$9.9M+52.3%	$6.5M+28.7%	$5.0M
Operating Income	-$24.1M+8.7%	-$26.3M-22.9%	-$21.4M+0.7%	-$21.6M-51.2%	-$14.3M-40.5%	-$10.2M
Interest Expense	$61K+916.7%	$6K	N/A	N/A	N/A	N/A
Income Tax	N/A	$0+100.0%	-$1.6M-15.1%	-$1.4M	$0	$0
Net Income	-$23.7M+7.5%	-$25.7M-39.8%	-$18.3M+6.8%	-$19.7M-38.0%	-$14.3M-42.1%	-$10.0M
EPS (Diluted)	$-2.08	$-19.03	$-28.48	$-1.31+31.1%	$-1.90-187.9%	$-0.66

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	$2.6M+30.6%	$2.0M-34.2%	$3.0M	N/A	$2.7M-7.4%	$3.0M-14.6%	$3.5M
SG&A Expenses	N/A	$1.9M-83.1%	$11.2M+671.5%	$1.4M	N/A	$2.3M+56.9%	$1.5M-24.1%	$1.9M
Operating Income	N/A	-$4.4M+66.2%	-$13.1M-197.3%	-$4.4M	N/A	-$7.9M+7.1%	-$8.5M-57.4%	-$5.4M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	-$4.4M+66.6%	-$13.1M-202.0%	-$4.3M	N/A	-$7.7M+7.1%	-$8.3M-61.0%	-$5.2M
EPS (Diluted)	N/A	$-0.45	$-1.93	$-1.55	N/A	$-6.81	$-10.72-42.4%	$-7.53

TOVX Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$38.2M+8.2%	$35.4M-36.0%	$55.2M-23.2%	$71.9M+2.1%	$70.4M+736.7%	$8.4M
Current Assets	$17.5M+7.3%	$16.3M-40.6%	$27.4M-39.8%	$45.5M-33.9%	$68.9M+767.9%	$7.9M
Cash & Equivalents	$13.1M+12.5%	$11.6M-49.9%	$23.2M-44.5%	$41.8M-37.9%	$67.3M+981.2%	$6.2M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	$0-100.0%	$5.7M+3.2%	$5.5M	$0	N/A
Total Liabilities	$22.9M+40.4%	$16.3M+4.9%	$15.5M-10.3%	$17.3M+248.9%	$5.0M-62.4%	$13.2M
Current Liabilities	$10.0M+32.0%	$7.6M+12.6%	$6.7M-4.6%	$7.1M+98.6%	$3.6M+19.8%	$3.0M
Long-Term Debt	$1.7M+1716.3%	$92K-43.2%	$162K-26.7%	$221K	N/A	N/A
Total Equity	$15.4M-19.3%	$19.1M-48.4%	$37.0M-28.7%	$51.8M-20.8%	$65.4M+1472.1%	-$4.8M
Retained Earnings	-$358.7M-7.1%	-$335.0M-8.3%	-$309.3M-6.3%	-$291.0M-7.3%	-$271.3M-9.3%	-$248.1M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$38.2M+24.0%	$30.8M-13.9%	$35.8M+11.4%	$32.2M-9.0%	$35.4M-11.9%	$40.1M-5.4%	$42.4M-13.0%	$48.7M
Current Assets	$17.5M+76.4%	$9.9M-32.8%	$14.7M+18.2%	$12.5M-23.4%	$16.3M-16.6%	$19.5M-0.9%	$19.7M-9.0%	$21.7M
Cash & Equivalents	$13.1M+73.4%	$7.5M-37.9%	$12.1M+21.0%	$10.0M-13.7%	$11.6M-29.3%	$16.4M-1.1%	$16.6M-9.1%	$18.3M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	$0	N/A	$1.5M-73.7%	$5.6M
Total Liabilities	$22.9M-5.2%	$24.1M-4.4%	$25.2M+51.3%	$16.7M+2.3%	$16.3M+5.2%	$15.5M+4.9%	$14.7M+0.9%	$14.6M
Current Liabilities	$10.0M-9.0%	$11.0M-11.2%	$12.4M+52.1%	$8.1M+7.4%	$7.6M+3.6%	$7.3M+6.9%	$6.8M+14.0%	$6.0M
Long-Term Debt	$1.7M	N/A	N/A	N/A	$92K	N/A	N/A	N/A
Total Equity	$15.4M+128.3%	$6.7M-36.6%	$10.6M-31.5%	$15.5M-18.7%	$19.1M-22.6%	$24.6M-4.9%	$25.9M-17.5%	$31.4M
Retained Earnings	-$358.7M-0.6%	-$356.7M-1.2%	-$352.4M-3.8%	-$339.3M-1.3%	-$335.0M-1.3%	-$330.5M-2.4%	-$322.8M-2.6%	-$314.5M

TOVX Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$16.7M+1.6%	-$16.9M+10.8%	-$19.0M+0.5%	-$19.1M-48.0%	-$12.9M-5.9%	-$12.2M
Capital Expenditures	$35K+3400.0%	$1K-99.5%	$202K+74.1%	$116K+728.6%	$14K+55.6%	$9K
Free Cash Flow	-$16.7M+1.4%	-$16.9M+11.8%	-$19.2M0.0%	-$19.2M-48.8%	-$12.9M-6.0%	-$12.2M
Investing Cash Flow	-$35K-3400.0%	-$1K+99.5%	-$202K+95.4%	-$4.4M-31300.0%	-$14K-55.6%	-$9K
Financing Cash Flow	$18.2M+231.0%	$5.5M+779.4%	$625K+132.4%	-$1.9M-102.6%	$74.0M+2103.1%	$3.4M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	$0-100.0%	$288K	$0	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	-$2.9M+33.3%	-$4.3M+8.3%	-$4.7M+0.9%	-$4.8M-1.4%	-$4.7M-19.9%	-$3.9M-13.4%	-$3.5M+29.3%	-$4.9M
Capital Expenditures	$0-100.0%	$19K	N/A	N/A	$0	$0	N/A	N/A
Free Cash Flow	-$2.9M+33.6%	-$4.3M	N/A	N/A	-$4.7M-19.9%	-$3.9M	N/A	N/A
Investing Cash Flow	$0+100.0%	-$19K	N/A	N/A	$0	$0	N/A	N/A
Financing Cash Flow	$8.5M+5814.9%	-$148K-102.2%	$6.8M+121.7%	$3.1M+43785.7%	$7K-99.8%	$3.7M	N/A	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

TOVX Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-154.3%-19.8pp	-134.5%-84.9pp	-49.6%-11.7pp	-38.0%-16.2pp	-21.8%	N/A
Return on Assets	-62.1%+10.5pp	-72.6%-39.3pp	-33.2%-5.8pp	-27.4%-7.1pp	-20.3%+99.1pp	-119.4%
Current Ratio	1.74-0.4	2.15-1.9	4.07-2.4	6.45-12.9	19.37+16.7	2.67
Debt-to-Equity	0.11+0.1	0.000.0	0.000.0	0.00-0.1	0.08+2.8	-2.76
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	-64.7%+58.2pp	-122.9%-95.0pp	-27.9%	N/A	-31.4%+0.8pp	-32.1%-15.7pp	-16.4%
Return on Assets	N/A	-14.1%+22.3pp	-36.4%-23.0pp	-13.4%	N/A	-19.3%+0.4pp	-19.6%-9.0pp	-10.6%
Current Ratio	1.74+0.8	0.90-0.3	1.19-0.3	1.53-0.6	2.15-0.5	2.67-0.2	2.88-0.7	3.60
Debt-to-Equity	0.11-3.5	3.58+1.2	2.37+1.3	1.08+1.1	0.00-0.6	0.63+0.1	0.57+0.1	0.47
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Xortx Therapeutics Inc XRTX

$3.2M

Galecto Inc. GLTO

$1.7B

Entero Therapeutics ENTO

$10.1M

Quoin Pharmaceuticals Ltd QNRX

$10.4M

Azitra Inc AZTR

$3.8M

Frequently Asked Questions

Is THERIVA BIOLOGICS INC profitable?

No, THERIVA BIOLOGICS INC (TOVX) reported a net income of -$23.7M in fiscal year 2025.

What is THERIVA BIOLOGICS INC's EBITDA?

THERIVA BIOLOGICS INC (TOVX) had EBITDA of -$23.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does THERIVA BIOLOGICS INC have?

As of fiscal year 2025, THERIVA BIOLOGICS INC (TOVX) had $13.1M in cash and equivalents against $1.7M in long-term debt.

What is THERIVA BIOLOGICS INC's return on equity (ROE)?

THERIVA BIOLOGICS INC (TOVX) has a return on equity of -154.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is THERIVA BIOLOGICS INC's free cash flow?

THERIVA BIOLOGICS INC (TOVX) generated -$16.7M in free cash flow during fiscal year 2025. This represents a 1.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is THERIVA BIOLOGICS INC's operating cash flow?

THERIVA BIOLOGICS INC (TOVX) generated -$16.7M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are THERIVA BIOLOGICS INC's total assets?

THERIVA BIOLOGICS INC (TOVX) had $38.2M in total assets as of fiscal year 2025, including both current and long-term assets.

What are THERIVA BIOLOGICS INC's capital expenditures?

THERIVA BIOLOGICS INC (TOVX) invested $35K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does THERIVA BIOLOGICS INC spend on research and development?

THERIVA BIOLOGICS INC (TOVX) invested $8.6M in research and development during fiscal year 2025.

How many shares does THERIVA BIOLOGICS INC have outstanding?

THERIVA BIOLOGICS INC (TOVX) had 36M shares outstanding as of fiscal year 2025.

What is THERIVA BIOLOGICS INC's current ratio?

THERIVA BIOLOGICS INC (TOVX) had a current ratio of 1.74 as of fiscal year 2025, which is generally considered healthy.

What is THERIVA BIOLOGICS INC's debt-to-equity ratio?

THERIVA BIOLOGICS INC (TOVX) had a debt-to-equity ratio of 0.11 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is THERIVA BIOLOGICS INC's return on assets (ROA)?

THERIVA BIOLOGICS INC (TOVX) had a return on assets of -62.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is THERIVA BIOLOGICS INC's cash runway?

Based on fiscal year 2025 data, THERIVA BIOLOGICS INC (TOVX) had $13.1M in cash against an annual operating cash burn of $16.7M. This gives an estimated cash runway of approximately 9 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is THERIVA BIOLOGICS INC's Piotroski F-Score?

THERIVA BIOLOGICS INC (TOVX) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are THERIVA BIOLOGICS INC's earnings high quality?

THERIVA BIOLOGICS INC (TOVX) has an earnings quality ratio of 0.70x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can THERIVA BIOLOGICS INC cover its interest payments?

THERIVA BIOLOGICS INC (TOVX) has an interest coverage ratio of -394.3x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.